On May 14, 2018, the expert council of St. Petersburg Special Economic Zone (SEZ) will review a business plan for building a plant to manufacture active pharmaceutical substances (active ingredients of medicinal products) at Novoorlovskaya site. This is the project of Baltfarma LLC.
Baltfarma applied for a land area of 1.4 hectares to build a production facility of about 4 thousand square meters. The investments are expected to reach 796 million rubles.
According to Zakhar Golant, Chairman of the Board of the Union “Medical and Pharmaceutical Projects of the 21st Century,” the production facility will include the areas for synthesis of complex chemical molecules in laboratory, pilot and industrial scales, focusing on production of small (from 10 g) and medium-tonnage (1 to 10 kg) lots of active substances. This will include primarily the molecules that have been recently excluded or will become excluded from patent protection in the coming years. Therefore, the products of the company are intended for plants manufacturing generics.
“We will look for the widest possible range of products with the minimum amount of synthesis. Currently, the company’s portfolio has 52 medicines, including those from the list of vital and essential drugs used for the treatment of cardiovascular, oncological, psychiatric, and other diseases,” said Zakhar Golant.
He expects to start commercial production in 2021.